1. PepGen faces a class action over misleading statements about PGN-EDO51. 2. Allegations suggest PGN-EDO51 is less effective and safe than claimed. 3. Defendants may halt CONNECT2 study based on negative findings. 4. Shareholders can register for potential recovery until August 2025. 5. False statements may have artificially inflated PEPG's stock price.
The allegations against PEPG suggest significant safety and efficacy concerns regarding its lead product, which could lead to a loss in investor confidence and a decrease in stock price, akin to past instances where misleading claims negatively impacted stock valuation.
Given the serious allegations of misleading information regarding PEPG’s lead drug, it’s highly likely the stock price will be adversely affected, making this a crucial event for investors.
The immediate implications of legal troubles and safety concerns could affect PEPG quickly, similar to how other biotech firms saw rapid declines following clinical issues.
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG).
Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=154641&from=4
CLASS PERIOD:
March 7, 2024 to March 3, 2025
ALLEGATIONS:
The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company's lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe; (ii) phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ("FDA") approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, defendants' public statements were materially false and misleading at all relevant times.
DEADLINE:
August 8, 2025. Shareholders should not delay in registering for this class action. Register your information here:
https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=154641&from=4
NEXT STEPS FOR SHAREHOLDERS:
Once you register as a shareholder who purchased shares of PEPG during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 8, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM?
The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903
SOURCE
The Gross Law Firm